EUVIMEDEUVIMED entdecken
Crossref

Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib

Xiongbing Lu, Chao Hu, Lingxing Duan, Ke Chen, Hua Hao, Yuanqiao He

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03666-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Xiongbing Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China. Hauptthemen laut MEDLINE: Benzimidazoles, Urinary Bladder Neoplasms, Organoids, Aminopyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province, Education Department of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Bladder cancer is one of the most common malignancies of the urinary system and there's a significant unmet need for new effective therapeutics for bladder cancer. The limited number of available models to study malignant bladder tumors is one of the obstructions in developing bladder cancer therapeutics. Patient-derived xenograft (PDX) and organoid (PDO) models are more representatives of human cancer than cell lines and cell line-derived xenograft (CDX) and are likely to be more promising and efficient in predicting drug response and finding new therapeutics. METHODS: Three pairs of patient-derived xenograft (PDX) models of bladder cancer and their corresponding PDX-derived organoids (PDXOs) were successfully established. These models were utilized to assess the efficacy of abemaciclib. The sensitivity of the drug was determined through the Cell Counting Kit-8 (CCK8) assay in PDXO cultures, corroborated by the EdU incorporation assay. Additionally, the in vivo tumor growth was monitored in the matched PDX models. RESULTS: In vitro PDXO cultures and in vivo PDX tumor models consistently demonstrated that abemaciclib had varying degrees of inhibitory effects across different bladder cancer (BC) patients. Notably, our study further revealed that treatment with abemaciclib significantly modified the expression patterns of CyclinD1/CDK4. This was achieved by not only diminishing their expression levels but also by shifting their expression from a membrane-associated localization to the nucleus. CONCLUSION: Our research provided compelling evidence attesting to the reliability and potential of PDX and PDXO models in the realm of precision medicine. These models are instrumental in identifying patients who are likely to respond favorably to a specific drug treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesUrinary Bladder NeoplasmsOrganoidsAminopyridinesAntineoplastic AgentsHumansAnimalsXenograft Model Antitumor AssaysMiceCell ProliferationCell Line, TumorCyclin-Dependent Kinase 4Female

Stichwörter der Autor:innen

AbemaciclibBladder cancerPDX-derived organoid (PDXO)Patient-derived xenograft (PDX)

Substanzen

BenzimidazolesabemaciclibAminopyridinesAntineoplastic AgentsCyclin-Dependent Kinase 4

Autor:innen und Institutionen

  • Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China.
  • Department of Pathology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, 200090, China.
  • Center of Laboratory Animal Science, Nanchang University, Nanchang, 330031, China. heyuanqiao@ncu.edu.cn.
  • Jiangxi Province Key Laboratory of Laboratory Animal, Nanchang, 330031, China. heyuanqiao@ncu.edu.cn.
  • Nanchang Royo Biotech Co, Ltd., Nanchang, 330000, China. heyuanqiao@ncu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangxi Province
  • Education Department of Jiangxi Province

Zitieren

APA

Lu, X., Hu, C., Duan, L., Chen, K., Hao, H., & He, Y. (2024). Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03666-3

Vancouver

Lu X, Hu C, Duan L, Chen K, Hao H, He Y. Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03666-3

BibTeX
@article{Lu2024,
  author = {Lu, Xiongbing and Hu, Chao and Duan, Lingxing and Chen, Ke and Hao, Hua and He, Yuanqiao},
  title = {Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03666-3}
}
Kostenlos starten →